Form 4: Coherus Oncology Director Rita Karachun Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Rita A. Karachun was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.

Summary

• Rita A. Karachun, a Director of Coherus Oncology, Inc. (CHRS), acquired 112,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $0.7904.
• The options entitle the holder to purchase 112,000 shares of Coherus Oncology Common Stock.
• The options will vest and become exercisable as to 100% of the total number of shares on the one-year anniversary of June 11, 2025, which is June 11, 2026.
• Vesting is contingent upon Ms. Karachun's continued service relationship with the Issuer on the vesting date.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Ms. Karachun beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, indicating confidence and a long-term commitment, which is a standard and expected compensation practice.

Positives

• The grant of stock options aligns the interests of Director Rita A. Karachun with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The options have a long expiration date (June 12, 2035), providing a significant window for potential value realization.

Risks

• The value of the stock options is dependent on the future market price of Coherus Oncology's common stock; if the stock price does not rise above the exercise price of $0.7904, the options may expire worthless.
• Vesting of the options is subject to the reporting person's continued service relationship with the Issuer, meaning the options could be forfeited if the service relationship terminates before the vesting date.

Future Outlook

The future outlook for the granted options is tied to the company's stock performance, with the options vesting fully on June 11, 2026, contingent on the director's continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common in the biotechnology and pharmaceutical industries where equity compensation is a standard component of executive and director remuneration to align long-term interests.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across publicly traded companies, particularly in the biotechnology sector, as a form of long-term incentive and to align director interests with shareholder value creation.
• The vesting schedule (100% after one year) is a typical, though sometimes more aggressive, vesting schedule for director grants, often seen as a way to quickly align new or existing directors with company performance.

Related Party Transactions

• The grant of stock options to Rita A. Karachun, a Director of Coherus Oncology, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive for shareholders as it aligns the director's financial interests with the company's stock performance, potentially incentivizing decisions that enhance shareholder value. However, future exercise of these options could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest on June 11, 2026, subject to the director's continued service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 12, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Coherus Oncology, CHRS, SEC Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership